Credits: Canva
When the sun is out after a long winter, every one loves it. But not the people of Canary Islands. Tourists there are being warned about the "unusually high risk" of UV rays this week. The Ministry of Health for this holiday destination has urged both, residents and visitors to take extra precautions and preventative measures to limit the impact of sun exposure over their body and skin.
The Ministry observed Aemet, Spain's national weather agency for the forecast which showed higher than normal UV or ultraviolet radiation levels in the region. It is in this backdrop that everyone in the region are requested to be extra careful when they are out in the sun. UV levels are set to reach 7, which is a 'high risk' in La Palma, El Hierro, La Gomera and Gran Canaria. Other regions like Tenerife, Fuerteventura and Lanzarote are expected to reach a level 6, which is also classed as 'high risk'.
As per the World Health Organization (WHO), a UV index is a measure of the level of UV radiation, which ranges from zero upward. The higher the UVI, the greater potential for damage to skin and eye and the less time it takes for harm to occur, notes WHO.
The range 1 to 2 represents a low risk, 2 to 5 is moderate, 6 to 7 is at high risk, 8 to 10 is at very high and anything over 11 is extremely risky for anyone to stay out.
UV radiation levels fluctuate throughout the day, with the highest values occurring during the four-hour period around solar noon. The reported UV Index (UVI) typically reflects this daily peak. Depending on geographic location and the use of daylight saving time, solar noon falls between 12 p.m. and 2 p.m. In some countries, sun protection advisories are issued when UV levels are expected to reach 3 or higher, as exposure at these levels increases the risk of skin damage, making protective measures essential.
While sun bathing is good, being out in the sun when the UVI indicates a high or very high risk, may cause you health concerns. It can lead to sunburn, premature skin aging, incresed risk of skin cancer, eye damage and in severe cases, heat related disease.
It is one of the most common skin injury which happens when there is excess exposure to UV radiation from the sun. This happens when the UV radiation directly damages the DNA skin cells. These damaged cells die and shed, this is why people experience peeling after getting a sunburn.
This is also a common occurrence when your body loses too many fluids or electrolytes. It can also interfere with your normal body functions. You may feel dehydrated, especially when you are out in the sun, but not well hydrated. The most common symptoms are dizziness, fatigue and headache on hot days.
This is an electrolyte disorder in which your body experiences low sodium in blood. The symptoms could lead to nausea, confusion and even weakness. There are extreme cases when one may have seizures, slip into coma or die.
This is one of the most common consequence of being out under the hot sun. Dehydration with prolonged heat exposure can lead to heat exhaustion.
When you are out under the sun and your body's core temperature cross 104°, heatstroke may occur. This is also known as sunstroke. As per the Centers for Disease Control and Prevention (CDC), it causes more than 600 deaths each year in the United States.
Credits: Canva
A widely sold nasal spray is being pulled from shelves across the United States after tests revealed mold and microbial contamination, prompting officials to urge consumers to stop using it right away.
MediNatura New Mexico issued a voluntary recall of ReBoost Nasal Spray on Wednesday, the US Food and Drug Administration said in a public notice. The action follows findings that one specific lot of the product contained yeast and mold, along with unsafe levels of microbial contamination.
Laboratory testing also identified the presence of Achromobacter, a type of bacteria that can cause infections, particularly in people with weakened immune systems. The FDA has advised customers to immediately discontinue use of the affected nasal spray.
MediNatura New Mexico Inc. has voluntarily recalled its ReBoost Nasal Spray after the product was found to contain yeast, mold, and microbial contamination. One of the organisms identified was the bacteria Achromobacter, detected at levels higher than safety limits, according to the US Food and Drug Administration.
The FDA warned that use of the spray could result in severe health effects, particularly for people with weakened immune systems. The agency noted a real risk of serious and potentially life-threatening infections in this group.
The Hawaii State Department of Health, which also issued a recall notice, listed symptoms that may be linked to the contaminated spray. These include fever, sinus swelling, headaches, facial pain or pressure, and numbness in the face.
Consumers who notice any of these symptoms after using the product have been advised to contact a doctor or healthcare provider.
As of December 10, MediNatura said it had not received any reports of health problems related to the recalled nasal spray. This information was confirmed by both the FDA and the Hawaii health department.
As per NBC, the nasal spray company was contacted for comment but did not receive a response by the time of publication.
ReBoost Nasal Spray is a homeopathic product that contains echinacea and other natural ingredients. The company markets it as a remedy for nasal congestion and related symptoms.
The recall applies to sprays packaged in a white and yellow box containing a 20 mL bottle. The affected lot number is 224268, with an expiration date of December 2027. The product carries NDC number 62795-4005-9 and UPC 787647101863.
The FDA has urged customers to stop using the nasal spray right away. Those who bought it directly from MediNatura can request a refund by emailing recall@medinatura.com. Consumers who purchased it through other retailers should return it to the place of purchase.
The product was sold both online and in physical stores across the United States.
Credits: Canva
Danish drugmaker Novo Nordisk has officially introduced its widely known diabetes medication Ozempic in India, pricing the starter dose of 0.25 mg at ₹2,200 per week. According to a Reuters report, the injectable medicine will be available in three strengths in the country: 0.25 mg, 0.5 mg and 1 mg.
Ozempic is a once-weekly injectable prescribed for people living with type 2 diabetes.
The weekly injection received approval from the US Food and Drug Administration in 2017 for treating type 2 diabetes. Since then, it has grown into a global blockbuster and is also commonly prescribed off-label for weight loss because of its appetite-suppressing effects.
The lowest strength will cost ₹2,200 per week. Prices for the higher doses have also been announced, as per the Reuters report.
Here are the details:
India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic, also known as semaglutide, in October this year for adults with type 2 diabetes.
As per the US FDA, Ozempic is prescribed along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes who already have heart disease.
As per NDTV Profit, currently, Wegovy is priced at Rs 2,712 per week for the 0.25 mg dose, while the 0.5 mg dose costs Rs 3,462 weekly. The 1 mg dose is also priced at Rs 3,462 per week, and the 1.7 mg dose is available at Rs 4,100 per week. Mounjaro (tirzepatide), a combination therapy of GLP-1 receptor agonist and GIP that helps improve blood sugar control in adults with type 2 diabetes when paired with a healthy diet and regular exercise, is priced at Rs 13,500 per month for the 2.5 mg dose.
Ozempic mimics the action of a naturally occurring hormone called GLP-1. Here’s how it supports weight loss, as outlined in an earlier HT report.
As previously reported by Mayo Clinic, some potential side-effects of Ozempic include:
This article is intended for informational purposes only and should not be taken as a replacement for professional medical advice.
Credits: Canva
Anti-pollution measures under GRAP-3 came into force in Delhi on Saturday as air quality slipped into the “severe” bracket. By noon, the national capital reported an Air Quality Index of 405, according to figures released by the Central Pollution Control Board (CPCB). Earlier in the day, Delhi’s AQI hovered close to 390 during the morning hours.
Each winter, Delhi and the surrounding NCR (National Capital Region) bring in curbs under the Graded Response Action Plan, which divides air quality into four levels: Stage 1 (Poor, AQI 201–300), Stage 2 (Very Poor, AQI 301–400), Stage 3 (Severe, AQI 401–450) and Stage 4 (Severe Plus, AQI above 450).
Under GRAP-3, non-essential construction and demolition activities have been halted, along with stone crushing and mining operations. The measures also include restrictions on older diesel goods vehicles within Delhi. Schools up to Class 5 are required to move to a hybrid learning model, while offices across Delhi-NCR may function with only 50 per cent staff strength, as per Press Information Bureau.
Hazardous AQI levels have become a recurring feature across several parts of Delhi during the winter months. Quoting environmental experts, an IANS report linked the sharp decline in air quality to a mix of stagnant wind conditions, vehicle emissions, industrial pollution and seasonal factors such as crop residue burning in neighbouring states.
The biggest shift under the updated GRAP framework is that stricter steps will now come into force earlier, instead of waiting for air quality to deteriorate further.
As per Press Information Bureau, under the revised system, measures that were earlier reserved for Stage 4 will now apply at Stage 3 itself. This means that once the AQI reaches the 301–400 range, public, municipal and private offices will function with only 50 percent staff. Central government offices will also move to work-from-home at this stage, rather than waiting for the AQI to cross 450.
In the same way, actions that earlier fell under Stage 3 have now been pushed to Stage 2. As a result, staggered timings for government offices will begin as soon as the AQI enters the 201–300 category.
Stage 2 measures have also been advanced to Stage 1. This brings uninterrupted power supply arrangements into effect earlier, at an AQI level of 101–200, to reduce the need for diesel generator use and limit additional emissions.
In response to the worsening situation, the Delhi government confirmed that the Commission for Air Quality Management (CAQM) has activated all measures under Stage III of GRAP, which falls under the “Severe” air quality category with AQI levels between 401 and 450, across the entire NCR.
These Stage 3 curbs will apply in addition to the existing Stage I and Stage II measures. Authorities, including NCR Pollution Control Boards, have been instructed to step up enforcement to prevent further deterioration of air quality across the region.
Even as Stage III of the Graded Response Action Plan comes into force, certain essential activities and services will continue to operate to minimise disruption to daily life.
© 2024 Bennett, Coleman & Company Limited